Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application
Summary
USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.
What changed
USPTO published patent application US20260097076A1 disclosing engineered immune cells (T cells or NK cells) expressing anti-BCMA, anti-TACI, or bispecific anti-BCMA/anti-TACI chimeric antigen receptors for cancer therapy. The application further discloses 'armored' CAR-T or CAR-NK cells incorporating armor polypeptides to enhance cellular persistence and anti-tumor activity. The invention covers methods of manufacturing these engineered cells and their use in treating B-cell malignancies and other cancers.
Biotechnology companies and researchers developing CAR-based cellular therapies should monitor this application for competitive intelligence on BCMA/TACI targeting strategies. The inclusion of armor polypeptides and the bispecific BCMA/TACI format may represent differentiated approaches from existing CAR-T therapies. Patent prosecution history may reveal allowed claims relevant to autologous and allogeneic cell therapy manufacturing.
What to do next
- Monitor for patent prosecution updates
- Track competitor IP filings in BCMA/TACI CAR therapy space
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO B-CELL MATURE ANTIGEN (BCMA) AND/OR TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR (TACI)
Application US20260097076A1 Kind: A1 Apr 09, 2026
Inventors
Yan CHEN, Garima AGRAHARI, Kehao ZHAO, Jenna NGUYEN, Keming ZHANG, Ning JIANG, Katie O'CALLAGHAN
Abstract
Genetically engineered immune cells (e.g., T cells or NK cells) expressing anti-BCMA, anti-TACI, or anti-BCMA/anti-TACI chimeric antigen receptors and uses thereof in cancer therapy. In some embodiments, the genetically engineered immune cells may be armored CAR-T or CAR-NK cells, which further express an armor polypeptide for enhancing CAR-T or CAR-NK cell features.
CPC Classifications
A61K 35/17 A61K 40/11 A61K 40/15 A61K 40/31 A61K 40/4215 A61P 35/00 C07K 14/7051 C07K 14/70521 C07K 14/70575 C07K 14/70578 C07K 16/2878 C12N 15/86 A61K 2239/13 A61K 2239/17 A61K 2239/21 A61K 2239/29 C07K 2317/565 C07K 2317/622 C07K 2319/02 C12N 2740/15043
Filing Date
2023-09-20
Application No.
19112720
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.